DK2777695T3 - Formuleringer til en tight-junction-effektor - Google Patents

Formuleringer til en tight-junction-effektor Download PDF

Info

Publication number
DK2777695T3
DK2777695T3 DK14150323.5T DK14150323T DK2777695T3 DK 2777695 T3 DK2777695 T3 DK 2777695T3 DK 14150323 T DK14150323 T DK 14150323T DK 2777695 T3 DK2777695 T3 DK 2777695T3
Authority
DK
Denmark
Prior art keywords
composition
coating
peptide
gly
delayed release
Prior art date
Application number
DK14150323.5T
Other languages
English (en)
Inventor
Blake Paterson
Mark J Ginski
Original Assignee
Alba Therapeutics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alba Therapeutics Corp filed Critical Alba Therapeutics Corp
Application granted granted Critical
Publication of DK2777695T3 publication Critical patent/DK2777695T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/009—Sachets, pouches characterised by the material or function of the envelope
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Claims (13)

1. Sammensætning til oral dosering omfattende en virksom mængde af et peptid ifølge SEQ ID NO:1, og omfattende første partikler med forsinket frigivelse, som frigiver peptidet i en patients tolvfingertarm efter indgivelse, hvor de første partikler med forsinket frigivelse omfatter: en kernepartikel; en coating omfattende peptidet ifølge SEQ ID NO:1 over kernepartiklen; og en coating med forsinket frigivelse uden om coatingen omfattende peptidet, hvor coatingen med forsinket frigivelse omfatter 1:1 co-polymer af poly-methacrylsyre og ethylacrylat; hvor coatingen med forsinket frigivelse er stabil i simuleret mavevæske og frigiver mindst 70 % af peptidet i de første partikler med forsinket frigivelse med ca. 90 minutters eksposition for simuleret tarmvæske med en pH-værdi på mere end 5.
2. Sammensætning til oral dosering ifølge krav 1, omfattende andre partikler med forsinket frigivelse, som frigiver peptidet i jejunum af en patient, hvor de andre partikler med forsinket frigivelse omfatter: en kernepartikel; en coating omfattende peptidet ifølge SEQ ID NO:1 over kernepartiklen; og en coating med forsinket frigivelse uden om coatingen omfattende peptidet, hvor coatingen med forsinket frigivelse omfatter 1:1 co-polymer af poly-methacrylsyre og ethylacrylat; hvor coatingen med forsinket frigivelse er stabil i simuleret mavevæske.
3. Sammensætning ifølge krav 1, hvor kernepartiklerne har en gennemsnitlig størrelse på fra 15 til 40 mesh.
4. Sammensætning ifølge krav 1, hvor kernepartikelmaterialet omfatter et sukkerstof, en oxid, cellulose, en organisk polymer eller et uorganisk salt.
5. Sammensætning ifølge krav 1, yderligere omfattende et overcoat-lag, der er påført over coatingen med forsinket frigivelse.
6. Sammensætning ifølge krav 5, hvor overcoat-laget omfatter hydroxypropylmethylcellulose (HPMC), sukker, polyethylenglycol, polyvinylpyrrolidon, poly-vinylalkohol, polyvinylacetat, hydroxypropylcellulose, methylcellulose og/eller ethylcellulose.
7. Sammensætning ifølge krav 1, hvor coatingen omfattende peptidet ifølge SEQ ID NO:1 yderligere omfatter et farmaceutisk acceptabelt bindemiddel, hvor bindemidlet eventuelt omfatter et sukkerstof, methylcellulose, polyvinylpyrrolidon, hydroxypropylcellulose, hydroxymethylcellulose og mikrokry-stallinsk cellulose.
8. Sammensætning ifølge krav 1, hvor coatingen med forsinket frigivelse yderligere omfatter talkum, et inert forarbejdningshjælpestof og/eller blødgører, eventuelt hvor det inerte forarbejdningshjælpestof omfatter siliconedioxid, talkum og/eller magnesiumstearat, og eventuelt hvor blødgøreren omfatter en citronsyreester, triacetin, phthalsyreester, dibutylsebacat, cetylalkohol, polyethylenglycol og/eller polysorbat.
9. Sammensætning ifølge krav 1, hvor sammensætningen er en kapsel.
10. Sammensætning ifølge krav 1, hvor den simulerede mavevæske og den simulerede tarmvæske ikke indeholder enzymer.
11. Sammensætning ifølge krav 1, hvor sammensætningen omfatter peptidet med fra 0,1 % til ca. 6 % baseret på sammensætningens samlede vægt.
12. Sammensætning ifølge krav 1, hvor den simulerede mavevæske har en pH-værdi på ca. 1,2, og eventuelt hvor mindre end 8 % af peptidet frigives i nærvær af simuleret mavevæske på ca. 60 minutter.
13. Sammensætning ifølge krav 1 til anvendelse ved en fremgangsmåde til behandling af gastrointestinal inflammation, hvor fremgangsmåden omfatter at indgive sammensætningen til et individ med behov herfor, eventuelt hvor individet har cøliaki eller har inflammatorisk tarmsygdom.
DK14150323.5T 2006-02-09 2007-02-09 Formuleringer til en tight-junction-effektor DK2777695T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77145406P 2006-02-09 2006-02-09
EP07750332.4A EP1993357B1 (en) 2006-02-09 2007-02-09 Formulations for a tight junction effector

Publications (1)

Publication Number Publication Date
DK2777695T3 true DK2777695T3 (da) 2018-12-17

Family

ID=38372020

Family Applications (2)

Application Number Title Priority Date Filing Date
DK14150323.5T DK2777695T3 (da) 2006-02-09 2007-02-09 Formuleringer til en tight-junction-effektor
DK07750332.4T DK1993357T3 (da) 2006-02-09 2007-02-09 Formuleringer af en tight junction effektor

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK07750332.4T DK1993357T3 (da) 2006-02-09 2007-02-09 Formuleringer af en tight junction effektor

Country Status (19)

Country Link
US (5) US9265811B2 (da)
EP (2) EP1993357B1 (da)
JP (1) JP5398268B2 (da)
KR (1) KR101393652B1 (da)
CN (2) CN103301070A (da)
AR (1) AR060103A1 (da)
AU (1) AU2007215304B2 (da)
BR (1) BRPI0707616A2 (da)
CA (2) CA2638914C (da)
DK (2) DK2777695T3 (da)
ES (2) ES2459018T3 (da)
IL (2) IL193344A (da)
MX (1) MX2008010221A (da)
NZ (1) NZ570427A (da)
PH (1) PH12012501912B1 (da)
RU (1) RU2008136208A (da)
TW (1) TWI478721B (da)
WO (1) WO2007095092A2 (da)
ZA (1) ZA200807111B (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249067A1 (en) * 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease
US20100144646A1 (en) * 2006-11-03 2010-06-10 Blake Paterson Method of diagnosing and treating asthma
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
ES2393814T3 (es) 2007-04-04 2012-12-28 Sigmoid Pharma Limited Una composición farmacéutica oral
US20110201543A1 (en) * 2007-06-29 2011-08-18 Blake Paterson Use of tight junction antagonists in the treatment of acute lung injury and acute respiratory distress
EP2062909A1 (en) * 2007-11-21 2009-05-27 SOLVAY (Société Anonyme) Peptide production and purification process
US9051349B2 (en) 2007-11-21 2015-06-09 Alba Therapeutics Corporation Larazotide acetate compositions
ES2343499B1 (es) * 2007-12-24 2011-06-10 Consejo Superior De Investigaciones Cientificas Microorganismos para mejorar el estado de salud de individuos con desordenes relacionados con la ingesta de gluten.
WO2009137572A2 (en) * 2008-05-06 2009-11-12 Alba Therapeutics Corporation Inhibition of gliadin peptides
ES2530049T3 (es) 2009-05-18 2015-02-26 Sigmoid Pharma Limited Composición que comprende gotas de aceite
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) * 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
US20130243829A1 (en) * 2010-10-01 2013-09-19 Joseph C. Ramaekers Enhancement of immune response by transfer factor
GB201020032D0 (en) 2010-11-25 2011-01-12 Sigmoid Pharma Ltd Composition
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
GB201212010D0 (en) 2012-07-05 2012-08-22 Sigmoid Pharma Ltd Formulations
JP5877935B2 (ja) 2012-10-17 2016-03-08 メチレーション・サイエンシーズ・インターナショナル・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティＭｅｔｈｙｌａｔｉｏｎ Ｓｃｉｅｎｃｅｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｓｒｌ Ｓ−アデノシルメチオニンおよび没食子酸エステルを含む組成物
AU2014239883B2 (en) 2013-03-14 2019-01-17 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
GB201319791D0 (en) 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
US20160022760A1 (en) 2014-04-04 2016-01-28 Wendy Perrow Methods of treating celiac disease with larazotide
JP6716582B2 (ja) 2014-11-07 2020-07-01 サブリミティ・セラピューティクス・リミテッドＳｕｂｌｉｍｉｔｙ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ シクロスポリンを含む組成物
PL3458067T3 (pl) * 2016-05-18 2021-12-13 Torqur Ag Leczenie chorób neurologicznych
MX2018014167A (es) * 2016-05-18 2019-08-16 Piqur Therapeutics Ag Tratamiento de lesiones de la piel.
EP3554494A4 (en) * 2016-12-19 2021-02-17 Cellixbio Private Limited INFLAMMATION TREATMENT COMPOSITIONS AND METHODS
CA3052975A1 (en) * 2017-02-10 2018-08-16 Innovate Biopharmaceuticals, Inc. Compositions and methods for treating disease associated with permeability of intestinal epithelium
EP3459528B1 (en) * 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
US12016889B2 (en) 2018-02-23 2024-06-25 9 Meters Biopharma, Inc. Compositions and methods for treating or preventing intestinal paracellular permeability
US11608359B2 (en) 2018-02-23 2023-03-21 9 Meters Biopharma, Inc. Compounds and methods for treating tight junction permeabtility
US20210361734A1 (en) 2018-03-19 2021-11-25 9 Meters Biopharma, Inc. Compositions and methods for potentiating immune checkpoint inhibitor therapy
WO2020227341A1 (en) 2019-05-06 2020-11-12 9 Meters Biopharma, Inc. Compositions and methods for treating sjogren's syndrome
CA3150380A1 (en) * 2019-08-16 2021-02-25 9 Meters Biopharma, Inc. Larazotide formulations
US20230181471A1 (en) * 2020-07-09 2023-06-15 Hoffmann-La Roche Inc. Concentrated compositions of proteins, their preparation and use thereof
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso
WO2024238657A2 (en) 2023-05-15 2024-11-21 Bonafide Health, Llc Sleep-improving compositions and methods of use

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643602A (en) * 1989-11-22 1997-07-01 Astra Aktiebolag Oral composition for the treatment of inflammatory bowel disease
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
WO1994011508A2 (en) 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
JP2996864B2 (ja) 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US20020094346A1 (en) * 1995-05-17 2002-07-18 M. D. Henry C. Lin Method and compositions for improving digestion and absorption in the small intestine
US5827534A (en) 1995-05-24 1998-10-27 University Of Maryland At Baltimore Oral dosage composition comprising zonnula occludens toxin and a therapeutic agent for intestinal delivery
US5665389A (en) * 1995-05-24 1997-09-09 University Of Maryland At Baltimore Oral dosage composition for intestinal delivery and method of treating diabetes
NZ331866A (en) 1996-03-15 2000-05-26 Corixa Corp Compounds for immunotherapy and immunodiagnosis of prostate cancer
US5908825A (en) 1997-01-09 1999-06-01 University Of Maryland At Baltimore Dosage composition for nasal delivery and method of use of the same
US5864014A (en) * 1997-02-20 1999-01-26 University Of Maryland At Baltimore Zonula occludens toxin receptor
US5912323A (en) 1997-02-20 1999-06-15 University Of Maryland, Baltimore Zonula occludens toxin receptors
US5945510A (en) * 1997-05-21 1999-08-31 University Of Maryland, Baltimore Substantially pure zonulin, a physiological modulator of mammalian tight junctions
US6506577B1 (en) * 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6458925B1 (en) * 1998-08-03 2002-10-01 University Of Maryland, Baltimore Peptide antagonists of zonulin and methods for use of the same
US6733762B1 (en) * 1998-09-14 2004-05-11 University Of Maryland, Baltimore Method of using Zot to inhibit lymphocyte proliferation in an antigen-specific manner
MXPA01004381A (es) * 1998-11-02 2005-09-08 Elan Corp Plc Composicion de multiparticulado de liberacion modificada.
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US20030180352A1 (en) * 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
AU2001249067A1 (en) * 2000-05-19 2001-12-03 University Of Maryland, Baltimore Method of use of peptide antagonists of zonulin to prevent or delay the onset ofdiabetes
US6897205B2 (en) 2001-01-31 2005-05-24 Roehm Gmbh & Co. Kg Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
MXPA05000128A (es) * 2002-07-05 2005-09-30 Temrel Inc Composicion de liberacion controlada.
DE10332160A1 (de) * 2003-07-15 2005-02-03 Röhm GmbH & Co. KG Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Peptid- oder Protein-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform
EP1648917A4 (en) * 2003-07-15 2008-11-12 Univ Maryland AGONISTPOLYPEPTIDE OF THE RECEPTOR FOR ZOT AND ZONULIN
PE20060003A1 (es) * 2004-03-12 2006-03-01 Smithkline Beecham Plc Formulacion farmaceutica polimerica para moldear por inyeccion
AU2006247731A1 (en) * 2005-05-13 2006-11-23 University Of Maryland - Baltimore Method for assessing the effectiveness of a treatment regimen by determining zonulin
ES2459018T3 (es) 2006-02-09 2014-05-07 Alba Therapeutics Corporation Formulaciones de efectores de la unión estrecha
WO2008043107A2 (en) * 2006-10-06 2008-04-10 Alba Therapeutics Corporation Use of tight junction antagonists to treat inflammatory bowel disease
US8034776B2 (en) * 2006-10-26 2011-10-11 Alba Therapeutics Corporation Materials and methods for the treatment of celiac disease

Also Published As

Publication number Publication date
US20070196501A1 (en) 2007-08-23
TWI478721B (zh) 2015-04-01
BRPI0707616A2 (pt) 2011-05-10
DK1993357T3 (da) 2014-04-22
CA2838399C (en) 2017-03-07
US20150164978A1 (en) 2015-06-18
IL228532A0 (en) 2013-12-31
JP5398268B2 (ja) 2014-01-29
RU2008136208A (ru) 2010-03-20
WO2007095092A3 (en) 2008-09-12
EP2777695A1 (en) 2014-09-17
ES2459018T3 (es) 2014-05-07
US20130122086A1 (en) 2013-05-16
EP2777695B1 (en) 2018-09-12
WO2007095092A2 (en) 2007-08-23
AU2007215304B2 (en) 2012-06-14
IL193344A (en) 2013-10-31
CA2638914A1 (en) 2007-08-23
CN101420850A (zh) 2009-04-29
EP1993357A2 (en) 2008-11-26
HK1126088A1 (en) 2009-08-28
EP1993357A4 (en) 2012-08-15
CA2838399A1 (en) 2007-08-23
AU2007215304A1 (en) 2007-08-23
PH12012501912A1 (en) 2014-09-08
US9241969B2 (en) 2016-01-26
CN103301070A (zh) 2013-09-18
US9265811B2 (en) 2016-02-23
EP1993357B1 (en) 2014-01-22
US20210154260A1 (en) 2021-05-27
JP2009527468A (ja) 2009-07-30
CA2638914C (en) 2014-04-08
KR20080108986A (ko) 2008-12-16
HK1202072A1 (en) 2015-09-18
TW200808339A (en) 2008-02-16
IL193344A0 (en) 2009-08-03
US20100279954A1 (en) 2010-11-04
US8168594B2 (en) 2012-05-01
AR060103A1 (es) 2008-05-28
ES2700278T3 (es) 2019-02-14
ZA200807111B (en) 2009-11-25
NZ570427A (en) 2011-10-28
PH12012501912B1 (en) 2014-09-08
KR101393652B1 (ko) 2014-05-14
MX2008010221A (es) 2009-03-05

Similar Documents

Publication Publication Date Title
DK2777695T3 (da) Formuleringer til en tight-junction-effektor
KR101873075B1 (ko) 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제
JP2005508922A6 (ja) プロプラノロールの時限徐放性多粒子剤型
WO2003051343A1 (en) Pulsatile release histamine h2 antagonist dosage forms
JP2005508922A (ja) プロプラノロールの時限徐放性多粒子剤型
HUE029680T2 (en) Dispensing systems containing weakly basic active ingredients and organic acids
KR20070046152A (ko) 미코페놀산 또는 미코페놀산나트륨을 포함하는 제약다중미립자 조성물 및 라파마이신과의 조합 조성물
CN114514031A (zh) 拉拉唑肽制剂
AU2012203787B2 (en) Formulations for a Tight Junction Effector
HK1202072B (en) Formulations for a tight junction effector
HK1126088B (en) Formulations for a tight junction effector
WO2020243393A1 (en) Design of a single oral delivery system containing a monoclonal antibody for the simultaneous treatment of chron&#39;s disease and ulcerative colitis